Mark Breidenbach
Stock Analyst at Oppenheimer
(1.72)
# 3,335
Out of 5,173 analysts
48
Total ratings
30.91%
Success rate
1.15%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mark Breidenbach
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALLO Allogene Therapeutics | Maintains: Outperform | $9 → $7 | $2.44 | +186.89% | 6 | Aug 1, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $27 → $30 | $14.69 | +104.22% | 4 | Sep 4, 2024 | |
| ARVN Arvinas | Reiterates: Outperform | $95 | $10.32 | +820.54% | 6 | Aug 9, 2023 | |
| IMRX Immuneering | Reiterates: Outperform | $25 | $5.12 | +388.28% | 3 | Aug 8, 2023 | |
| CUE Cue Biopharma | Assumes: Outperform | $10 | $0.27 | +3,656.57% | 6 | Jun 26, 2023 | |
| MCRB Seres Therapeutics | Assumes: Outperform | $240 | $8.67 | +2,668.17% | 4 | Jun 26, 2023 | |
| BLRX BioLineRx | Reiterates: Outperform | $160 | $2.32 | +6,796.55% | 1 | May 25, 2023 | |
| CGEN Compugen | Maintains: Outperform | $8 → $7 | $2.09 | +234.93% | 7 | May 16, 2023 | |
| CRBU Caribou Biosciences | Maintains: Outperform | $36 → $32 | $1.86 | +1,620.43% | 2 | Mar 10, 2023 | |
| IOVA Iovance Biotherapeutics | Maintains: Outperform | $25 → $15 | $3.63 | +313.22% | 7 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11,250 → $9,750 | $0.81 | +1,199,900.00% | 2 | May 12, 2020 |
Allogene Therapeutics
Aug 1, 2025
Maintains: Outperform
Price Target: $9 → $7
Current: $2.44
Upside: +186.89%
Nurix Therapeutics
Sep 4, 2024
Maintains: Outperform
Price Target: $27 → $30
Current: $14.69
Upside: +104.22%
Arvinas
Aug 9, 2023
Reiterates: Outperform
Price Target: $95
Current: $10.32
Upside: +820.54%
Immuneering
Aug 8, 2023
Reiterates: Outperform
Price Target: $25
Current: $5.12
Upside: +388.28%
Cue Biopharma
Jun 26, 2023
Assumes: Outperform
Price Target: $10
Current: $0.27
Upside: +3,656.57%
Seres Therapeutics
Jun 26, 2023
Assumes: Outperform
Price Target: $240
Current: $8.67
Upside: +2,668.17%
BioLineRx
May 25, 2023
Reiterates: Outperform
Price Target: $160
Current: $2.32
Upside: +6,796.55%
Compugen
May 16, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $2.09
Upside: +234.93%
Caribou Biosciences
Mar 10, 2023
Maintains: Outperform
Price Target: $36 → $32
Current: $1.86
Upside: +1,620.43%
Iovance Biotherapeutics
Mar 1, 2023
Maintains: Outperform
Price Target: $25 → $15
Current: $3.63
Upside: +313.22%
May 12, 2020
Maintains: Outperform
Price Target: $11,250 → $9,750
Current: $0.81
Upside: +1,199,900.00%